320 related articles for article (PubMed ID: 19365125)
1. Botulinum neurotoxin: the ugly duckling.
Koussoulakos S
Eur Neurol; 2009; 61(6):331-42. PubMed ID: 19365125
[TBL] [Abstract][Full Text] [Related]
2. Botulinum neurotoxin intramuscular chemodenervation. Role in the management of spastic hypertonia and related motor disorders.
Yablon SA
Phys Med Rehabil Clin N Am; 2001 Nov; 12(4):833-74, vii-viii. PubMed ID: 11723867
[TBL] [Abstract][Full Text] [Related]
3. Expanding use of botulinum toxin.
Bhidayasiri R; Truong DD
J Neurol Sci; 2005 Aug; 235(1-2):1-9. PubMed ID: 15990116
[TBL] [Abstract][Full Text] [Related]
4. The action of batulinum toxin at the neuromuscular junction.
Sellin LC
Med Biol; 1981 Feb; 59(1):11-20. PubMed ID: 6115105
[TBL] [Abstract][Full Text] [Related]
5. [Mechanism of action and therapeutic uses of botulinum and tetanus neurotoxins].
Popoff MR; Marvaud JC; Raffestin S
Ann Pharm Fr; 2001 May; 59(3):176-90. PubMed ID: 11427819
[TBL] [Abstract][Full Text] [Related]
6. Botulinum toxin: a dreaded toxin for use in human being.
Ghosh B; Das SK
J Indian Med Assoc; 2002 Oct; 100(10):607-8, 610-2, 614. PubMed ID: 12452515
[TBL] [Abstract][Full Text] [Related]
7. Physiological effects of botulinum toxin in spasticity.
Gracies JM
Mov Disord; 2004 Mar; 19 Suppl 8():S120-8. PubMed ID: 15027064
[TBL] [Abstract][Full Text] [Related]
8. Botulinum toxins: pharmacology and its current therapeutic evidence for use.
Panicker JN; Muthane UB
Neurol India; 2003 Dec; 51(4):455-60. PubMed ID: 14742921
[TBL] [Abstract][Full Text] [Related]
9. [Mode of action and effects of botulinum neurotoxin A].
Périé S; Lacau St-Guily J
Ann Otolaryngol Chir Cervicofac; 1996; 113(2):73-8. PubMed ID: 8999747
[TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin: from poison to remedy.
Kessler KR; Benecke R
Neurotoxicology; 1997; 18(3):761-70. PubMed ID: 9339823
[TBL] [Abstract][Full Text] [Related]
11. Botulinum neurotoxin type E: studies on mechanism of action and on structure-activity relationships.
Simpson LL; Dasgupta BR
J Pharmacol Exp Ther; 1983 Jan; 224(1):135-40. PubMed ID: 6294275
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxins in neurological disease.
Comella CL; Pullman SL
Muscle Nerve; 2004 May; 29(5):628-44. PubMed ID: 15116366
[TBL] [Abstract][Full Text] [Related]
13. Botulinum neurotoxins: mechanism of action and therapeutic applications.
Montecucco C; Schiavo G; Tugnoli V; de Grandis D
Mol Med Today; 1996 Oct; 2(10):418-24. PubMed ID: 8897436
[TBL] [Abstract][Full Text] [Related]
14. Beyond BOTOX: advantages and limitations of individual botulinum neurotoxins.
Davletov B; Bajohrs M; Binz T
Trends Neurosci; 2005 Aug; 28(8):446-52. PubMed ID: 15979165
[TBL] [Abstract][Full Text] [Related]
15. In vitro characterization of botulinum toxin types A, C and D action on human tissues: combined electrophysiologic, pharmacologic and molecular biologic approaches.
Coffield JA; Bakry N; Zhang RD; Carlson J; Gomella LG; Simpson LL
J Pharmacol Exp Ther; 1997 Mar; 280(3):1489-98. PubMed ID: 9067339
[TBL] [Abstract][Full Text] [Related]
16. Botulinum neurotoxin in muscle overactivity.
Esquenazi A
J Head Trauma Rehabil; 2005; 20(6):563-7. PubMed ID: 16304491
[No Abstract] [Full Text] [Related]
17. Botulin toxin: a weapon in terrorism.
Josko D
Clin Lab Sci; 2004; 17(1):30-4. PubMed ID: 15011978
[TBL] [Abstract][Full Text] [Related]
18. Clostridial toxins as therapeutic agents: benefits of nature's most toxic proteins.
Johnson EA
Annu Rev Microbiol; 1999; 53():551-75. PubMed ID: 10547701
[TBL] [Abstract][Full Text] [Related]
19. Clostridium botulinum neurotoxin.
Sugiyama H
Microbiol Rev; 1980 Sep; 44(3):419-48. PubMed ID: 6252433
[No Abstract] [Full Text] [Related]
20. The interaction between aminoquinolines and presynaptically acting neurotoxins.
Simpson LL
J Pharmacol Exp Ther; 1982 Jul; 222(1):43-8. PubMed ID: 6283072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
